Haleon PLC's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 72/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.58.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Haleon PLC's Score
Industry at a Glance
Industry Ranking
72 / 159
Overall Ranking
182 / 4592
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
10.579
Target Price
+12.54%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Haleon PLC Highlights
StrengthsRisks
Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 8.92B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 41.40%.
Undervalued
The company’s latest PE is 38.90, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 570.14M shares, decreasing 2.78% quarter-over-quarter.
Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.
Ticker SymbolHLN
CompanyHaleon PLC
CEOMcnamara (Brian)
Websitehttps://www.haleon.com/
FAQs
What is the current price of Haleon PLC (HLN)?
The current price of Haleon PLC (HLN) is 9.520.
What is the symbol of Haleon PLC?
The ticker symbol of Haleon PLC is HLN.
What is the 52-week high of Haleon PLC?
The 52-week high of Haleon PLC is 11.420.
What is the 52-week low of Haleon PLC?
The 52-week low of Haleon PLC is 8.710.
What is the market capitalization of Haleon PLC?
The market capitalization of Haleon PLC is 85.53B.
What is the net income of Haleon PLC?
The net income of Haleon PLC is 1.44B.
Is Haleon PLC (HLN) currently rated as Buy, Hold, or Sell?
According to analysts, Haleon PLC (HLN) has an overall rating of Buy, with a price target of 10.579.
What is the Earnings Per Share (EPS TTM) of Haleon PLC (HLN)?
The Earnings Per Share (EPS TTM) of Haleon PLC (HLN) is 0.245.